An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
Study record managers: refer to the Data Element Definitions if submitting registration or results information.| clinicaltrials.gov
No description.| ALS News Today
ALS is a neurodegenerative disorder marked by progressively worsening muscle weakness and neurological dysfunction.| ALS News Today
Category archive page for News.| ALS News Today
Margarida Maia is a science writer for ALS News Today with a PhD in biomedical sciences. She covers the latest news and information on a variety of amyotrophic lateral sclerosis topics.| ALS News Today
ALS is a progressive neurological disorder that damages motor neurons. Learn more about types, causes, symptoms, diagnosis, and treatment.| ALS News Today
Learn about Parkinson's disease, a condition that affects the brain, resulting in issues with movement, balance, and more.| Parkinson's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today